ReviewCellular and molecular gastroenterology and hepatology2019
Circulating Hybrid Cells Join the Fray of Circulating Cellular Biomarkers.
Review in Cellular and molecular gastroenterology and hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Considerations for the use of targeted fluorescence contrast agents to detect circulating cancer cell populations with diffuseJournal of biomedical optics · 2026Article
- The influence of cell-cell fusion on cancer heterogeneity and its promise for targeted treatments.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- The authors respond to feedback onFrontiers in oncology · 2026Article
- Implications of Heterotypic Cell Fusion in Cancer.Advances in experimental medicine and biology · 2026Review
- Quantitative image analysis pipeline for detecting circulating hybrid cells in immunofluorescence images with human-level accuracy.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2024Article
- Article
- Extracellular Vesicles, Circulating Tumor Cells, and Immune Checkpoint Inhibitors: Hints and Promises.Cells · 2024Review
- The Hallmarks of Circulating Hybrid Cells.Results and problems in cell differentiation · 2024Review
- A Multifunctional Delivery System for Remodulating Cell Behaviors of Circulating Malignant Cells to Prevent Cell Fusion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS).Medical oncology (Northwood, London, England) · 2023Article
- Fusion Cell Markers in Circulating Tumor Cells from Patients with High-Grade Ovarian Serous Carcinoma.International journal of molecular sciences · 2022Article
- Review
- Mutation in SF3B1 gene promotes formation of polyploid giant cells in Leukemia cells.Medical oncology (Northwood, London, England) · 2022Article
- Hybrid/Atypical Forms of Circulating Tumor Cells: Current State of the Art.Biochemistry. Biokhimiia · 2022Review
- Synergistic Analysis of Circulating Tumor Cells Reveals Prognostic Signatures in Pilot Study of Treatment-Naïve Metastatic Pancreatic Cancer Patients.Biomedicines · 2022Article
- Circulating Hybrid Cells: A Novel Liquid Biomarker of Treatment Response in Gastrointestinal Cancers.Annals of surgical oncology · 2021Article
- Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors.Scientific reports · 2021Article
- Article
- Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal.Cellular and molecular life sciences : CMLS · 2020Review
- A Snapshot of The Tumor Microenvironment in Colorectal Cancer: The Liquid Biopsy.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Gastrointestinal cancers account for more cancer-related deaths than any other organ system, owing in part to difficulties in early detection, treatment response assessment, and post-treatment surveillance. Circulating biomarkers hold the promise for noninvasive liquid biopsy platforms to overcome these obstacles. Although tumors shed detectable levels of degraded genetic material and cellular debris into peripheral blood, identifying reproducible and clinically relevant information from these analytes (eg, cell-free nucleotides, exosomes, proteins) has proven difficult. Cell-based circulating biomarkers also present challenges, but have multiple advantages including allowing for a more comprehensive tumor analysis, and communicating the risk of metastatic spread. Circulating tumor cells have dominated the cancer cell biomarker field with robust evidence in extraintestinal cancers; however, establishing their clinical utility beyond that of prognostication in colorectal and pancreatic cancers has remained elusive. Recently identified novel populations of tumor-derived cells bring renewed potential to this area of investigation. Cancer-associated macrophage-like cells, immune cells with phagocytosed tumor material, also show utility in prognostication and assessing treatment responsiveness. In addition, circulating hybrid cells are the result of tumor-macrophage fusion, with mounting evidence for a role in the metastatic cascade. Because of their relative abundance in circulation, circulating hybrid cells have great potential as a liquid biomarker for early detection, prognostication, and surveillance. In all, the power of the cell reaches beyond enumeration by providing a cellular source of tumor DNA, RNA, and protein, which can be harnessed to impact overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.